Profusa Set to Share Insights at Leipzig Interventional Course
Profusa, Inc., a pioneering digital health company, is excited to announce their upcoming presentation at the Leipzig Interventional Course (LINC) 2026. This esteemed event will take place from January 27 to January 30, 2026, in Leipzig, Germany. The Company will showcase insights from its latest clinical study focusing on its Lumee technology, aimed at transforming the care of patients with peripheral artery disease (PAD).
Understanding the Lumee Technology
At the heart of Profusa’s innovation is the Lumee oxygen tissue monitoring technology, a breakthrough that enables continuous and real-time measurement of tissue oxygen levels directly within the body. This capability is revolutionary as it allows for monitoring in both clinical environments and at home, offering a significant enhancement in patient care standards.
Dr. Ben Hwang, the Chairman and CEO of Profusa, highlighted the positive feedback from their clinical study aimed at evaluating this pioneering technology. He expressed eagerness to share additional clinical results at LINC, providing an opportunity for valuable discussions with healthcare providers and researchers attending the conference.
Insights from the US-Based Clinical Study
The upcoming presentation will occur on January 28 at 9:45 am CET, where attendees can expect in-depth insights regarding tissue oxygen monitoring for patients with PAD. This information is gathered from Profusa’s pilot clinical study conducted at various sites across the U.S. The focus on PAD is particularly crucial, as this condition affects many individuals globally and is associated with significant health risks.
Why This Presentation Matters
Presenting at an influential conference like LINC is a significant milestone for Profusa and its stakeholders. It not only showcases the Company's commitment to advancing health technology but also facilitates critical engagement with experts in the field. Profusa aims to revolutionize the way clinicians monitor and manage patients' health through innovative wearable technologies, supporting both individual and community health outcomes.
About Profusa
Headquartered in Berkeley, California, Profusa is a dedicated digital health company with a vision for a future where technology and healthcare seamlessly integrate. With its team of expert researchers and a strong board of directors, Profusa is at the forefront of developing a new generation of tissue-integrated sensors that are designed to deliver actionable, medical-grade data to users. Their long-lasting and injectable biosensors are part of a broader strategy to create a personalized biochemical signature that clinicians can trust.
The Broader Impact of Lumee Technology
Profusa’s commitment to creating affordable, reliable, and intelligent health monitoring solutions reflects a broader trend in healthcare where precision and personalization are becoming paramount. The Lumee technology not only aims to enhance individual health management but also represents a step towards more effective systemic healthcare approaches.
Frequently Asked Questions
What is the significance of the Leipzig Interventional Course for Profusa?
The course provides an opportunity for Profusa to present its innovative Lumee technology, enabling important discussions surrounding advancements in digital health.
What are the main benefits of the Lumee technology?
Lumee enables continuous, real-time monitoring of tissue oxygen, enhancing patient care both in clinics and at home.
How does Profusa approach its clinical studies?
Profusa conducts thorough studies in collaboration with U.S. sites to ensure reliable data and outcomes for its technologies.
What conditions does the Lumee technology aim to address?
Primarily, Lumee targets patients with peripheral artery disease (PAD), a condition associated with significant health challenges.
How can individuals learn more about Profusa?
Interested individuals can visit Profusa’s official site for further information regarding their innovations and clinical developments.